Printed From BioPortfolio.com
STAT Plus: Spark’s novel gene therapy for blindness is racing to a historic date with the FDA
04:30 EDT 9 Oct 2017 | STAT
An FDA approval of Spark's Luxturna would be historic, as the first true gene therapy in the U.S. It might also carry a $1 million price tag.
Original Article: STAT Plus: Spark’s novel gene therapy for blindness is racing to a historic date with the FDA
